GUARDION HEALTH SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.065 USD | +0.81% |
|
-2.33% | +49.06% |
| Mar. 29 | Guardion Health Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 05 | North American Morning Briefing : Hopes of March -2- | DJ |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 36.66 | 15.81 | 8.938 | 6.81 | 10.27 | - |
| Enterprise Value (EV) 1 | 36.66 | 15.81 | 8.938 | 6.81 | 10.27 | 10.27 |
| P/E ratio | -4.15 x | -0.62 x | -0.51 x | 44.5 x | -3.33 x | -7.84 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 2.19 x | 0.81 x | 0.56 x | 0.76 x | 0.69 x |
| EV / Revenue | - | 2.19 x | 0.81 x | 0.56 x | 0.76 x | 0.69 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 294 | 489 | 1,232 | 1,275 | 1,284 | - |
| Reference price 2 | 124.5 | 32.36 | 7.255 | 5.340 | 8.000 | 8.000 |
| Announcement Date | 3/26/21 | 3/31/22 | 4/17/23 | 3/29/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 7.233 | 11.05 | 12.25 | 13.45 | 14.8 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -24.75 | -17.42 | -4.336 | -3.755 | -3.409 |
| Operating Margin | - | -342.13% | -157.66% | -35.4% | -27.92% | -23.04% |
| Earnings before Tax (EBT) | - | - | - | - | - | - |
| Net income 1 | -8.572 | -24.75 | -15.86 | 0.158 | -3.742 | -3.313 |
| Net margin | - | -342.11% | -143.57% | 1.29% | -27.82% | -22.39% |
| EPS 2 | -30.00 | -52.00 | -14.15 | 0.1200 | -2.400 | -1.020 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/26/21 | 3/31/22 | 4/17/23 | 3/29/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.627 | 2.385 | 3.275 | 2.664 | 2.726 | 3.186 | 2.79 | 3.337 | 2.936 | 3.122 | 3.208 | 3.504 | 3.616 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -14.52 | -2.62 | -1.712 | -1.739 | -11.35 | -1.464 | -1.013 | -0.7729 | -1.087 | -1.177 | -0.913 | -0.837 | -0.828 |
| Operating Margin | -552.67% | -109.87% | -52.26% | -65.3% | -416.29% | -45.96% | -36.3% | -23.16% | -37.02% | -37.7% | -28.46% | -23.89% | -22.9% |
| Earnings before Tax (EBT) | - | - | -1.702 | -1.696 | - | - | -1.172 | - | - | - | - | - | - |
| Net income 1 | -14.52 | -2.618 | -1.702 | -1.696 | -9.847 | 0.5331 | -1.172 | 0.3726 | 0.4247 | -1.174 | -0.91 | -0.833 | -0.825 |
| Net margin | -552.63% | -109.81% | -51.96% | -63.68% | -361.18% | 16.73% | -42.02% | 11.17% | 14.47% | -37.6% | -28.37% | -23.77% | -22.82% |
| EPS 2 | -30.00 | -3.500 | -1.500 | -1.500 | -7.650 | 0.4200 | -0.9300 | 0.2900 | 0.3300 | -0.8800 | -0.6600 | -0.5800 | -0.2800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/31/22 | 5/12/22 | 8/11/22 | 11/14/22 | 4/17/23 | 5/15/23 | 8/14/23 | 11/13/23 | 3/29/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 0.07 | - | - | - | - |
| Capex / Sales | - | 1.03% | - | - | - | - |
| Announcement Date | 3/26/21 | 3/31/22 | 4/17/23 | 3/29/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +49.06% | 10.27M | |
| +30.49% | 699B | |
| +25.07% | 571B | |
| -4.78% | 364B | |
| +18.08% | 326B | |
| +2.76% | 286B | |
| +14.68% | 236B | |
| +4.71% | 198B | |
| -12.43% | 194B | |
| -3.14% | 154B |
- Stock Market
- Equities
- GHSI Stock
- Financials Guardion Health Sciences, Inc.
